NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage biopharma company developing oral, non-statin medicines for cardiovascular disease patients, announced its participation in three major investor conferences in June 2025:
1. William Blair Growth Stock Conference (Chicago) - June 3, featuring CEO Michael Davidson presenting a corporate overview at 3:20 PM CT
2. Jefferies Global Healthcare Conference (New York) - June 4, with CFO Ian Somaiya in a fireside chat at 10:30 AM ET
3. Goldman Sachs Healthcare Conference (Miami) - June 9, featuring CEO Michael Davidson and EVP Matthew Phillipe in a fireside chat at 2:40 PM ET
Live webcasts will be available through NewAmsterdam's investor relations website, with archived replays accessible afterward.
NewAmsterdam Pharma (Nasdaq: NAMS), un'azienda biofarmaceutica in fase avanzata che sviluppa farmaci orali non a base di statine per pazienti con malattie cardiovascolari, ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel giugno 2025:
1. William Blair Growth Stock Conference (Chicago) - 3 giugno, con il CEO Michael Davidson che presenterà una panoramica aziendale alle 15:20 CT
2. Jefferies Global Healthcare Conference (New York) - 4 giugno, con il CFO Ian Somaiya in una conversazione informale alle 10:30 ET
3. Goldman Sachs Healthcare Conference (Miami) - 9 giugno, con il CEO Michael Davidson e l'EVP Matthew Phillipe in una conversazione informale alle 14:40 ET
Saranno disponibili webcast in diretta tramite il sito web delle relazioni con gli investitori di NewAmsterdam, con repliche archiviate accessibili successivamente.
NewAmsterdam Pharma (Nasdaq: NAMS), una compañía biofarmacéutica en etapa avanzada que desarrolla medicamentos orales no basados en estatinas para pacientes con enfermedades cardiovasculares, anunció su participación en tres importantes conferencias para inversores en junio de 2025:
1. William Blair Growth Stock Conference (Chicago) - 3 de junio, con el CEO Michael Davidson presentando una visión general corporativa a las 3:20 PM CT
2. Jefferies Global Healthcare Conference (Nueva York) - 4 de junio, con el CFO Ian Somaiya en una charla informal a las 10:30 AM ET
3. Goldman Sachs Healthcare Conference (Miami) - 9 de junio, con el CEO Michael Davidson y el EVP Matthew Phillipe en una charla informal a las 2:40 PM ET
Habrá transmisiones en vivo disponibles a través del sitio web de relaciones con inversores de NewAmsterdam, con repeticiones archivadas accesibles posteriormente.
NewAmsterdam Pharma (나스닥: NAMS)는 심혈관 질환 환자를 위한 경구용 비스타틴 약물을 개발하는 후기 단계 바이오제약 회사로, 2025년 6월에 열리는 세 개의 주요 투자자 컨퍼런스에 참여한다고 발표했습니다:
1. William Blair Growth Stock Conference (시카고) - 6월 3일, CEO 마이클 데이비드슨이 오후 3시 20분 CT에 기업 개요 발표
2. Jefferies Global Healthcare Conference (뉴욕) - 6월 4일, CFO 이안 소마이야가 오전 10시 30분 ET에 파이어사이드 채팅 참여
3. Goldman Sachs Healthcare Conference (마이애미) - 6월 9일, CEO 마이클 데이비드슨과 EVP 매튜 필립이 오후 2시 40분 ET에 파이어사이드 채팅 참여
라이브 웹캐스트는 NewAmsterdam 투자자 관계 웹사이트를 통해 제공되며, 이후에 녹화 재방송도 이용할 수 있습니다.
NewAmsterdam Pharma (Nasdaq : NAMS), une entreprise biopharmaceutique en phase avancée développant des médicaments oraux non statines pour les patients atteints de maladies cardiovasculaires, a annoncé sa participation à trois grandes conférences pour investisseurs en juin 2025 :
1. William Blair Growth Stock Conference (Chicago) - 3 juin, avec le PDG Michael Davidson présentant une vue d'ensemble de l'entreprise à 15h20 CT
2. Jefferies Global Healthcare Conference (New York) - 4 juin, avec le directeur financier Ian Somaiya lors d'une discussion informelle à 10h30 ET
3. Goldman Sachs Healthcare Conference (Miami) - 9 juin, avec le PDG Michael Davidson et le vice-président exécutif Matthew Phillipe lors d'une discussion informelle à 14h40 ET
Des webcasts en direct seront disponibles via le site web des relations investisseurs de NewAmsterdam, avec des rediffusions archivées accessibles par la suite.
NewAmsterdam Pharma (Nasdaq: NAMS), ein Biopharmaunternehmen in der Spätphase, das orale, nicht-statinbasierte Medikamente für Patienten mit Herz-Kreislauf-Erkrankungen entwickelt, gab seine Teilnahme an drei wichtigen Investorenkonferenzen im Juni 2025 bekannt:
1. William Blair Growth Stock Conference (Chicago) – 3. Juni, mit CEO Michael Davidson, der um 15:20 Uhr CT eine Unternehmensübersicht präsentiert
2. Jefferies Global Healthcare Conference (New York) – 4. Juni, mit CFO Ian Somaiya in einem Fireside Chat um 10:30 Uhr ET
3. Goldman Sachs Healthcare Conference (Miami) – 9. Juni, mit CEO Michael Davidson und EVP Matthew Phillipe in einem Fireside Chat um 14:40 Uhr ET
Live-Webcasts werden über die Investor-Relations-Website von NewAmsterdam verfügbar sein, mit anschließendem Zugriff auf archivierte Wiedergaben.
- None.
- None.
NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
- William Blair 45th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 3, 2025. Michael Davidson, M.D., Chief Executive Officer, will present a corporate overview at 3:20 p.m. CT on Tuesday, June 3.
- Jefferies Global Healthcare Conference 2025 in New York, NY on Wednesday, June 4, 2025. Ian Somaiya, Chief Financial Officer, will participate in a fireside chat at 10:30 a.m. ET on Wednesday, June 4.
- Goldman Sachs 46th Annual Healthcare Conference in Miami, FL on Monday, June 9, 2025. Michael Davidson, M.D., Chief Executive Officer, and Matthew Phillipe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 2:40 p.m. ET on Monday, June 9.
Live webcasts of these presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcasts, archived replays will be available on the Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Spectrum Science on behalf of NewAmsterdam
Jaryd Leady
P: 1-856-803-7855
jleady@spectrumscience.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com
FAQ
What investor conferences will NewAmsterdam Pharma (NAMS) attend in June 2025?
Who will represent NewAmsterdam Pharma (NAMS) at these investor conferences?
How can investors access NewAmsterdam Pharma's (NAMS) conference presentations?
What is NewAmsterdam Pharma's (NAMS) main business focus?
